


## Promising New Biomarker For Pancreatic Cancer

# PAUF

## Discovery and Development of Future Biologics


PAUF (Pancreatic Adenocarcinoma Up-regulated Factor) is a biomarker over-expressed in over 80% of pancreatic adenocarcinoma, as well as other cancers like ovarian and prostate cancer.




# PAUF

**P**ancreatic **A**denocarcinoma **U**p-regulated **F**actor  
Promising New Biomarker For Pancreatic Cancer

## TME modulator




- The tumor microenvironment (TME) in pancreatic cancer contributes to tumor progression in a multifaceted way.
- PAUF is called TME modulator which promotes cancer progression and metastasis via multiple pathways by stimulating cancer cell and stroma cell.
  - Induces angiogenesis and vascular permeability
  - Promotes cancer metastasis
  - Causes suppressive tumor micro-environment (TME)
  - Induces resistance to chemotherapeutics




## Over-expressed in Pancreatic Cancer

PAUF Expression in Pancreatic Tissues




Survival of Pancreatic Cancer Patients with Difference Level of PAUF Expression



PAUF is over-expressed in over 80% of pancreatic adenocarcinoma.  
Reducing PAUF may improve survival of pancreatic cancer patients.

**Early Diagnosis & Precision Treatment**



### Research Papers related to PAUF

- [1] PAUF Induces Migration of Human Pancreatic Cancer Cells Exclusively via the TLR4/MyD88/NF- $\kappa$ B Signalling Pathway. *Oncotarget* (2022).
- [2] PAUF enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. *Oncotarget* (2016).
- [3] A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis. *Biochem Biophys Res Commun* (2014).
- [4] PAUF, a novel endothelial activator, promotes angiogenesis and vascular permeability. *Oncogene* (2013).
- [5] PAUF promotes metastasis by regulating TLR/CXCR4 activation. *Oncogene* (2011).
- [6] PAUF, a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. *Cancer Sci* (2009).



**Secreted protein** involved in pancreatic cancer progression and metastasis  
**Novel target** for the treatment and diagnosis of pancreatic cancer.

## Promising New Biomarker For Pancreatic Cancer

# PAUF

From diagnosis and prediction to precision treatment

### Problem

Deadliest of solid malignancies  
 Late Diagnosis at advanced stage  
 Chemo/Radiation resistance

### Needs

New therapeutics  
 Early detection technologies

### Solution

#### Treatment




First-in-Class pancreatic cancer treatment to target PAUF

PBP1510 (INN: Ulenistamab)	
Indication	Pancreatic Cancer, Ovarian Cancer
Category	Monoclonal antibody
Development Stage	Phase 1/2a (EU, USA & Asia)

PBP1510 specifically binds to PAUF and exerts anti-metastasis and immune modulation effects. PBP1510 demonstrates efficacy in Subcutaneous or Orthotopic Patient-derived Tumor Models. Eligible patients with Advanced/Metastatic Pancreatic Cancer will be effectively treated with PBP1510.



#### Diagnosis



PAUF detection in blood as pancreatic cancer screening


PAUF Detection Kit	
Indication	Pancreatic Cancer
Category	Diagnostic Kit
Development Stage	Discovery

Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for pancreatic cancer so far, but it has low specificity.

The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF.

In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.






## Pipeline Highlights

First-in-Class Antibody Therapeutics

**PBP1510**  
Anti-PAUF, Ulenistamab



FDA ORPHAN DRUG DESIGNATION    FDA FAST TRACK DESIGNATION

**First-in-Class Antibody PBP1510 (ulenistamab)**

- Development stage : Phase 1/2a (EU, USA & Asia)
- Indication : Pancreatic cancer, Ovarian cancer
- Orphan Drug Designation by FDA, EMA, MFDS
- Fast Track Designation by FDA
- Target on Pancreatic Cancer



**First-in-Class Antibody PBP1710 (Anti-CTHRC1)**

- Development stage : Preclinical
- Indication : Solid tumors
- Patent registered in Korea in January 2023
- Target on Solid Tumor

Category	Pipeline	Indication	Development Status
Bispecific antibody	IDC 001	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific antibody	IDC 002	Pancreatic cancer, Ovarian cancer	Target Identification & Validation
Bispecific antibody	IDC 003	Solid tumors	Target Identification & Validation
Bispecific antibody	IDC 004	Pancreatic cancer, Ovarian cancer	Target Identification & Validation
Bispecific antibody	IDC 005	Solid tumors	Lead Discovery & Optimization
Bispecific antibody	IDC 007	Critical immune disorders	Lead Discovery & Optimization
Bispecific antibody	IDC 008	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific antibody	IDC 009	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific antibody	IDC 010	Immune diseases	Lead Discovery & Optimization
Novel Concept Antibody	IDC 331	Solid tumors	Target Identification & Validation
Novel Concept Antibody	IDC 332	Solid tumors	Target Identification & Validation



### Corporate Headquarters

21 Biopolis Road, #04-24/28  
Nucleos South Building, Singapore 138567  
Tel: +65 6924 6535  
Email: info@prestigebio.com

### Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.  
2776-8, Myeongji-dong, Gangseo-gu,  
Busan 618-814, South Korea  
Tel: +65 51 580 8000  
Email: info@prestigebio.com

a member of **CANCER MOONSHOT**

